Serotonergic psychedelic: Difference between revisions

Line 16:

The cortico-striato-thalamo-cortical loops (also known as CSTC-loops) appear to be central to the function of psychedelics,<ref>Taylor, S. B., Lewis, C. R., & Olive, M. F. (2013). The neurocircuitry of illicit psychostimulant addiction: acute and chronic effects in humans. Substance Abuse and Rehabilitation, 4, 29–43. https://doi.org/10.2147/SAR.S39684; [..] The overall output of the basal ganglia is predominantly via the thalamus, which then projects back to the PFC to form cortico-striatal-thalamo-cortical (CSTC) loops. [..]</ref> which are also regulated by the serotonergic system. These control loops connect brain areas like the frontal lobe, the striatum and the thalamus; they aggregate, process and forward internal and external information.

The disruption of the neurotransmitter balance causes these control loops to collapse overwhelmed, leading to the flooding of the frontal lobe with neuronal excitatory glutamate; internal and external stimuli as well as all kinds of non-conscious contents can freely move up to the cerebral cortex and appear as visions in consciousness.<ref>Vollenweider, F. X. (2001). Brain mechanisms of hallucinogens and entactogens. Dialogues in Clinical Neuroscience, 3(4), 265–79. Retrieved from ~~http~~://~~www~~.~~pubmedcentral~~.~~nih~~.~~gov/articlerender~~.~~fcgi?artid=3181663&tool=pmcentrez&rendertype=abstract~~</ref><ref>[http://~~www~~.~~neuroculturelab.com/portfolio/edelrausch-im-labor~~/ Edelrausch im Labor] – ''Neuro Culture Lab'' (German)</ref>

The disruption of the neurotransmitter balance causes these control loops to collapse overwhelmed, leading to the flooding of the frontal lobe with neuronal excitatory glutamate; internal and external stimuli as well as all kinds of non-conscious contents can freely move up to the cerebral cortex and appear as visions in consciousness.<ref>Vollenweider, F. X. (2001). Brain mechanisms of hallucinogens and entactogens. Dialogues in Clinical Neuroscience, 3(4), 265–79. Retrieved from https://doi.org/10.31887%2FDCNS.2001.3.4%2Ffxvollenweider</ref><ref>[http://archive.today/jcBm Edelrausch im Labor] – ''Neuro Culture Lab'' (German)</ref>

Furthermore, over-activation of the ''locus coeruleus'' and subsequent widespread [[norepinephrine]] secretion may occur, causing a perceived state of sensory transcendence and sometimes even intense spiritual or [[transpersonal]] experiences.

Line 23:

==Examples==

<h3 class="panel-header">[[Lysergamides]][[File:book.svg|x20px|right|link=]]</h3>

~~<h4 class="media-heading"></h4>~~

* [[1B-LSD]]

*[[1B-LSD]]

* [[1P-ETH-LAD]]

*[[1P-ETH-LAD]]

* [[1P-LSD]]

*[[1P-LSD]]

* [[AL-LAD]]

*[[AL-LAD]]

* [[ALD-52]]

*[[ALD-52]]

* [[ETH-LAD]]

*[[ETH-LAD]]

* [[LSA]]

*[[LSA]]

* [[LSD]]

*[[LSD]]

* [[LSM-775]]

*[[LSM-775]]

* [[LSZ]]

*[[LSZ]]

* [[MIPLA]]

*[[MIPLA]]

* [[PARGY-LAD]]

*[[PARGY-LAD]]

* [[PRO-LAD]]

*[[PRO-LAD]]

</li>

</ul>

Line 52:

<h4 class="media-heading">[[Base Tryptamines]]</h4>

* [[DET]]

*[[DET]]

* [[DiPT]]

*[[DiPT]]

* [[DMT]]

*[[DMT]]

* [[DPT]]

*[[DPT]]

* [[EiPT]]

*[[EiPT]]

* [[EPT]]

*[[EPT]]

* [[MET]]

*[[MET]]

* [[MiPT]]

*[[MiPT]]

* [[MPT]]

*[[MPT]]

* [[PiPT]]

*[[PiPT]]

* [[αMT]]

*[[αMT]]

</li>

<h4 class="media-heading">[[Substituted Tryptamines]]</h4>

* [[4-PO-DMT]] (''Psilocybin'')

*[[4-PO-DMT]] (''Psilocybin'')

* [[4-HO-DMT]] (''Psilocin'')

*[[4-HO-DMT]] (''Psilocin'')

* [[4-HO-MET]] (''Metocin'')

*[[4-HO-MET]] (''Metocin'')

* [[4-HO-DET]] (''Ethocin'')

*[[4-HO-DET]] (''Ethocin'')

* [[4-HO-MiPT]] (''Miprocin'')

*[[4-HO-MiPT]] (''Miprocin'')

* [[4-HO-DiPT]] (''Iprocin'')

*[[4-HO-DiPT]] (''Iprocin'')

* [[4-HO-MPT]]

*[[4-HO-MPT]]

* [[4-HO-EPT]]

*[[4-HO-EPT]]

* [[4-HO-DPT]]

*[[4-HO-DPT]]

* [[4-AcO-DMT]] (''Psilacetin'')

*[[4-AcO-DMT]] (''Psilacetin'')

* [[4-AcO-MET]] (''Metacetin'', ''Azomet'')

*[[4-AcO-MET]] (''Metacetin'', ''Azomet'')

* [[4-AcO-DET]] (''Ethacetin'')

*[[4-AcO-DET]] (''Ethacetin'')

* [[4-AcO-MiPT]] (''Mipracetin'')

*[[4-AcO-MiPT]] (''Mipracetin'')

* [[4-AcO-DiPT]] (''Ipracetin'')

*[[4-AcO-DiPT]] (''Ipracetin'')

* [[4-AcO-MPT]]

*[[4-AcO-MPT]]

* [[4-AcO-EPT]]

*[[4-AcO-EPT]]

* [[4-AcO-DPT]]

*[[4-AcO-DPT]]

* [[5-HO-DMT]] (''Bufotenin'')

*[[5-HO-DMT]] (''Bufotenin'')

* [[5-MeO-DMT]]

*[[5-MeO-DMT]]

* [[5-MeO-MiPT]] (''Moxy'')

*[[5-MeO-MiPT]] (''Moxy'')

* [[5-MeO-DiPT]] (''Foxy'')

*[[5-MeO-DiPT]] (''Foxy'')

* [[5-MeO-DALT]]

*[[5-MeO-DALT]]

* [[5-MeO-MALT]]

*[[5-MeO-MALT]]

* [[Ibogaine]]

*[[Ibogaine]]

</li>

</ul>

Line 96:

</div>

<h3 class="panel-header">[[Phenethylamines]] [[File:flask.svg|x20px|right|link=]]</h3>

* [[Mescaline]]

*[[Mescaline]]

* [[Escaline]]

*[[Escaline]]

* [[Allylescaline]]

*[[Allylescaline]]

* [[Methallylescaline]]

*[[Methallylescaline]]

* [[Proscaline]]

*[[Proscaline]]

</li>

<h4 class="media-heading">[[2C-x]] series</h4>

* [[2C-B]]

*[[2C-B]]

* [[2C-C]]

*[[2C-C]]

* [[2C-D]]

*[[2C-D]]

* [[2C-E]]

*[[2C-E]]

* [[2C-H]]

*[[2C-H]]

* [[2C-I]]

*[[2C-I]]

* [[2C-P]]

*[[2C-P]]

* [[2C-TFM]]

*[[2C-TFM]]

* [[2C-T-2]]

*[[2C-T-2]]

* [[2C-T-7]]

*[[2C-T-7]]

</li>

<h4 class="media-heading">[[DOx]] series</h4>

* [[DOB]]

*[[DOB]]

* [[DOC]]

*[[DOC]]

* [[DOET]] (''DOE'')

*[[DOET]] (''DOE'')

* [[DOI]]

*[[DOI]]

* [[DOM]]

*[[DOM]]

* [[DOPR]]

*[[DOPR]]

</li>

<h4 class="media-heading">[[25x-NBOMe]]s</h4>

* [[25B-NBOMe]]

*[[25B-NBOMe]]

* [[25C-NBOMe]]

*[[25C-NBOMe]]

* [[25D-NBOMe]]

*[[25D-NBOMe]]

* [[25I-NBOMe]]

*[[25I-NBOMe]]

* [[25N-NBOMe]]

*[[25N-NBOMe]]

</li>

<h4 class="media-heading">Others</h4>

* [[2C-B-FLY]]

*[[2C-B-FLY]]

* [[Bromo-DragonFLY]]

*[[Bromo-DragonFLY]]

* [[ßk-2C-B]]

*[[ßk-2C-B]]

* [[TMA-2]]

*[[TMA-2]]

* [[TMA-6]]

*[[TMA-6]]

</ul>

</div>

<h3 class="panel-header">[[Entheogens]] [[File:users.svg|x20px|right|link=]]</h3>

* [[Acacia confusa]]

*[[Acacia confusa]]

* [[Ayahuasca]]

*[[Ayahuasca]]

* [[Hawaiian baby woodrose]]

*[[Hawaiian baby woodrose]]

* [[Iboga]]

*[[Iboga]]

* [[Mimosa hostilis]]

*[[Mimosa hostilis]]

* [[Morning glory]]

*[[Morning glory]]

* [[Psilocybin mushrooms]]

*[[Psilocybin mushrooms]]

* [[Yopo]]

*[[Yopo]]

</li>

</ul>

Line 172:

* [[5-MeO-DiBF]]

*[[5-MeO-DiBF]]

* [[Efavirenz]]

*[[Efavirenz]]

</li>

</ul>

Line 181:

==See also==

*[[Responsible use]]

*[[Serotonin]]

Line 190:

Line 191:

==External links==

*[https://en.wikipedia.org/wiki/Serotonergic_psychedelic Serotonergic psychedelic (Wikipedia)]

==Literature==

* {{cite journal|last1=Nichols|first1=D. E.|title=Psychedelics|journal=Pharmacological Reviews|volume=68|issue=2|year=2016|pages=264–355|issn=1521-0081|doi=10.1124/pr.115.011478}}

* {{cite journal|last1=Geyer|first1=M.A.|last2=Nichols|first2=D.E.|last3=Vollenweider|first3=F.X.|title=Serotonin-Related Psychedelic Drugs|year=2009|pages=731–738|doi=10.1016/B978-008045046-9.01160-8}}

*{{cite journal|last1=Nichols|first1=D. E.|title=Psychedelics|journal=Pharmacological Reviews|volume=68|issue=2|year=2016|pages=264–355|issn=1521-0081|doi=10.1124/pr.115.011478}}

* Nichols, C. D., & Sanders-Bush, E. (2001). "Serotonin Receptor Signaling and Hallucinogenic Drug Action". Heffter Rev Psychedelic Res, 2, 73-79. https://web-beta.archive.org/web/20170110205041/https://heffter.org/docs/hrireview/02/chap5.pdf

*{{cite journal|last1=Geyer|first1=M.A.|last2=Nichols|first2=D.E.|last3=Vollenweider|first3=F.X.|title=Serotonin-Related Psychedelic Drugs|year=2009|pages=731–738|doi=10.1016/B978-008045046-9.01160-8}}

* {{cite journal|last1=Halberstadt|first1=Adam L.|title=Recent advances in the neuropsychopharmacology of serotonergic hallucinogens|journal=Behavioural Brain Research|volume=277|year=2015|pages=99–120|issn=01664328|doi=10.1016/j.bbr.2014.07.016}}

*Nichols, C. D., & Sanders-Bush, E. (2001). "Serotonin Receptor Signaling and Hallucinogenic Drug Action". Heffter Rev Psychedelic Res, 2, 73-79. https://web-beta.archive.org/web/20170110205041/https://heffter.org/docs/hrireview/02/chap5.pdf

* {{cite journal|last1=Beique|first1=J.-C.|last2=Imad|first2=M.|last3=Mladenovic|first3=L.|last4=Gingrich|first4=J. A.|last5=Andrade|first5=R.|title=Mechanism of the 5-hydroxytryptamine 2A receptor-mediated facilitation of synaptic activity in prefrontal cortex|journal=Proceedings of the National Academy of Sciences|volume=104|issue=23|year=2007|pages=9870–9875|issn=0027-8424|doi=10.1073/pnas.0700436104}}

*{{cite journal|last1=Halberstadt|first1=Adam L.|title=Recent advances in the neuropsychopharmacology of serotonergic hallucinogens|journal=Behavioural Brain Research|volume=277|year=2015|pages=99–120|issn=01664328|doi=10.1016/j.bbr.2014.07.016}}

* {{cite journal|last1=Winter|first1=J.C|last2=Fiorella|first2=D.J|last3=Timineri|first3=D.M|last4=Filipink|first4=R.A|last5=Helsley|first5=S.E|last6=Rabin|first6=R.A|title=Serotonergic Receptor Subtypes and Hallucinogen-Induced Stimulus Control|journal=Pharmacology Biochemistry and Behavior|volume=64|issue=2|year=1999|pages=283–293|issn=00913057|doi=10.1016/S0091-3057(99)00063-5}}

*{{cite journal|last1=Beique|first1=J.-C.|last2=Imad|first2=M.|last3=Mladenovic|first3=L.|last4=Gingrich|first4=J. A.|last5=Andrade|first5=R.|title=Mechanism of the 5-hydroxytryptamine 2A receptor-mediated facilitation of synaptic activity in prefrontal cortex|journal=Proceedings of the National Academy of Sciences|volume=104|issue=23|year=2007|pages=9870–9875|issn=0027-8424|doi=10.1073/pnas.0700436104}}

* {{cite journal|last1=Nichols|first1=David E.|last2=Nichols|first2=Charles D.|title=Serotonin Receptors|journal=Chemical Reviews|volume=108|issue=5|year=2008|pages=1614–1641|issn=0009-2665|doi=10.1021/cr078224o}}

*{{cite journal|last1=Winter|first1=J.C|last2=Fiorella|first2=D.J|last3=Timineri|first3=D.M|last4=Filipink|first4=R.A|last5=Helsley|first5=S.E|last6=Rabin|first6=R.A|title=Serotonergic Receptor Subtypes and Hallucinogen-Induced Stimulus Control|journal=Pharmacology Biochemistry and Behavior|volume=64|issue=2|year=1999|pages=283–293|issn=00913057|doi=10.1016/S0091-3057(99)00063-5}}

* Canal, C. E., & Murnane, K. S. (2017). The serotonin 5-HT2C receptor and the non-addictive nature of classic hallucinogens. Journal of Psychopharmacology, 31(1), 127-143. https://doi.org/10.1177/0269881116677104

*{{cite journal|last1=Nichols|first1=David E.|last2=Nichols|first2=Charles D.|title=Serotonin Receptors|journal=Chemical Reviews|volume=108|issue=5|year=2008|pages=1614–1641|issn=0009-2665|doi=10.1021/cr078224o}}

*Canal, C. E., & Murnane, K. S. (2017). The serotonin 5-HT2C receptor and the non-addictive nature of classic hallucinogens. Journal of Psychopharmacology, 31(1), 127-143. https://doi.org/10.1177/0269881116677104

==References==

[[Category:Psychedelic]]

@@ Line 16: / Line 16: @@
 The cortico-striato-thalamo-cortical loops (also known as CSTC-loops) appear to be central to the function of psychedelics,<ref>Taylor, S. B., Lewis, C. R., & Olive, M. F. (2013). The neurocircuitry of illicit psychostimulant addiction: acute and chronic effects in humans. Substance Abuse and Rehabilitation, 4, 29–43. https://doi.org/10.2147/SAR.S39684; [..] The overall output of the basal ganglia is predominantly via the thalamus, which then projects back to the PFC to form cortico-striatal-thalamo-cortical (CSTC) loops. [..]</ref> which are also regulated by the serotonergic system. These control loops connect brain areas like the frontal lobe, the striatum and the thalamus; they aggregate, process and forward internal and external information.
-The disruption of the neurotransmitter balance causes these control loops to collapse overwhelmed, leading to the flooding of the frontal lobe with neuronal excitatory glutamate; internal and external stimuli as well as all kinds of non-conscious contents can freely move up to the cerebral cortex and appear as visions in consciousness.<ref>Vollenweider, F. X. (2001). Brain mechanisms of hallucinogens and entactogens. Dialogues in Clinical Neuroscience, 3(4), 265–79. Retrieved from http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3181663&tool=pmcentrez&rendertype=abstract</ref><ref>[http://www.neuroculturelab.com/portfolio/edelrausch-im-labor/ Edelrausch im Labor] – ''Neuro Culture Lab'' (German)</ref>
+The disruption of the neurotransmitter balance causes these control loops to collapse overwhelmed, leading to the flooding of the frontal lobe with neuronal excitatory glutamate; internal and external stimuli as well as all kinds of non-conscious contents can freely move up to the cerebral cortex and appear as visions in consciousness.<ref>Vollenweider, F. X. (2001). Brain mechanisms of hallucinogens and entactogens. Dialogues in Clinical Neuroscience, 3(4), 265–79. Retrieved from https://doi.org/10.31887%2FDCNS.2001.3.4%2Ffxvollenweider</ref><ref>[http://archive.today/jcBm Edelrausch im Labor] – ''Neuro Culture Lab'' (German)</ref>
 Furthermore, over-activation of the ''locus coeruleus'' and subsequent widespread [[norepinephrine]] secretion may occur, causing a perceived state of sensory transcendence and sometimes even intense spiritual or [[transpersonal]] experiences.
@@ Line 23: / Line 23: @@
 ==Examples==
-<div class='flex-panel'>
+<div class="flex-panel">
-     <div class='flex-column'>
+     <div class="flex-column">
          <div class="panel radius">
              <h3 class="panel-header">[[Lysergamides]][[File:book.svg|x20px|right|link=]]</h3>
              <ul class="featured-table">
                  <li class="featured list-item">
-                     <h4 class="media-heading"></h4>
-* [[1B-LSD]]
+*[[1B-LSD]]
-* [[1P-ETH-LAD]]
+*[[1P-ETH-LAD]]
-* [[1P-LSD]]
+*[[1P-LSD]]
-* [[AL-LAD]]
+*[[AL-LAD]]
-* [[ALD-52]]
+*[[ALD-52]]
-* [[ETH-LAD]]
+*[[ETH-LAD]]
-* [[LSA]]
+*[[LSA]]
-* [[LSD]]
+*[[LSD]]
-* [[LSM-775]]
+*[[LSM-775]]
-* [[LSZ]]
+*[[LSZ]]
-* [[MIPLA]]
+*[[MIPLA]]
-* [[PARGY-LAD]]
+*[[PARGY-LAD]]
-* [[PRO-LAD]]
+*[[PRO-LAD]]
                  </li>
              </ul>
@@ Line 52: / Line 52: @@
                  <li class="featured list-item">
                      <h4 class="media-heading">[[Base Tryptamines]]</h4>
-* [[DET]]
+*[[DET]]
-* [[DiPT]]
+*[[DiPT]]
-* [[DMT]]
+*[[DMT]]
-* [[DPT]]
+*[[DPT]]
-* [[EiPT]]
+*[[EiPT]]
-* [[EPT]]
+*[[EPT]]
-* [[MET]]
+*[[MET]]
-* [[MiPT]]
+*[[MiPT]]
-* [[MPT]]
+*[[MPT]]
-* [[PiPT]]
+*[[PiPT]]
-* [[αMT]]
+*[[αMT]]
                  </li>
                  <li class="featured list-item">
                      <h4 class="media-heading">[[Substituted Tryptamines]]</h4>
-* [[4-PO-DMT]] (''Psilocybin'')
+*[[4-PO-DMT]] (''Psilocybin'')
-* [[4-HO-DMT]] (''Psilocin'')
+*[[4-HO-DMT]] (''Psilocin'')
-* [[4-HO-MET]] (''Metocin'')
+*[[4-HO-MET]] (''Metocin'')
-* [[4-HO-DET]] (''Ethocin'')
+*[[4-HO-DET]] (''Ethocin'')
-* [[4-HO-MiPT]] (''Miprocin'')
+*[[4-HO-MiPT]] (''Miprocin'')
-* [[4-HO-DiPT]] (''Iprocin'')
+*[[4-HO-DiPT]] (''Iprocin'')
-* [[4-HO-MPT]]
+*[[4-HO-MPT]]
-* [[4-HO-EPT]]
+*[[4-HO-EPT]]
-* [[4-HO-DPT]]
+*[[4-HO-DPT]]
-* [[4-AcO-DMT]] (''Psilacetin'')
+*[[4-AcO-DMT]] (''Psilacetin'')
-* [[4-AcO-MET]] (''Metacetin'', ''Azomet'')
+*[[4-AcO-MET]] (''Metacetin'', ''Azomet'')
-* [[4-AcO-DET]] (''Ethacetin'')
+*[[4-AcO-DET]] (''Ethacetin'')
-* [[4-AcO-MiPT]] (''Mipracetin'')
+*[[4-AcO-MiPT]] (''Mipracetin'')
-* [[4-AcO-DiPT]] (''Ipracetin'')
+*[[4-AcO-DiPT]] (''Ipracetin'')
-* [[4-AcO-MPT]]
+*[[4-AcO-MPT]]
-* [[4-AcO-EPT]]
+*[[4-AcO-EPT]]
-* [[4-AcO-DPT]]
+*[[4-AcO-DPT]]
-* [[5-HO-DMT]] (''Bufotenin'')
+*[[5-HO-DMT]] (''Bufotenin'')
-* [[5-MeO-DMT]]
+*[[5-MeO-DMT]]
-* [[5-MeO-MiPT]] (''Moxy'')
+*[[5-MeO-MiPT]] (''Moxy'')
-* [[5-MeO-DiPT]] (''Foxy'')
+*[[5-MeO-DiPT]] (''Foxy'')
-* [[5-MeO-DALT]]
+*[[5-MeO-DALT]]
-* [[5-MeO-MALT]]
+*[[5-MeO-MALT]]
-* [[Ibogaine]]
+*[[Ibogaine]]
                  </li>
              </ul>
@@ Line 96: / Line 96: @@
      </div>
-     <div class='flex-column'>
+     <div class="flex-column">
          <div class="panel radius">
              <h3 class="panel-header">[[Phenethylamines]] [[File:flask.svg|x20px|right|link=]]</h3>
              <ul class="featured-table">
                  <li class="featured list-item">
-* [[Mescaline]]
+*[[Mescaline]]
-* [[Escaline]]
+*[[Escaline]]
-* [[Allylescaline]]
+*[[Allylescaline]]
-* [[Methallylescaline]]
+*[[Methallylescaline]]
-* [[Proscaline]]
+*[[Proscaline]]
                  </li>
                  <li class="featured list-item">
                      <h4 class="media-heading">[[2C-x]] series</h4>
-* [[2C-B]]
+*[[2C-B]]
-* [[2C-C]]
+*[[2C-C]]
-* [[2C-D]]
+*[[2C-D]]
-* [[2C-E]]
+*[[2C-E]]
-* [[2C-H]]
+*[[2C-H]]
-* [[2C-I]]
+*[[2C-I]]
-* [[2C-P]]
+*[[2C-P]]
-* [[2C-TFM]]
+*[[2C-TFM]]
-* [[2C-T-2]]
+*[[2C-T-2]]
-* [[2C-T-7]]
+*[[2C-T-7]]
                  </li>
                  <li class="featured list-item">
                      <h4 class="media-heading">[[DOx]] series</h4>
-* [[DOB]]
+*[[DOB]]
-* [[DOC]]
+*[[DOC]]
-* [[DOET]] (''DOE'')
+*[[DOET]] (''DOE'')
-* [[DOI]]
+*[[DOI]]
-* [[DOM]]
+*[[DOM]]
-* [[DOPR]]
+*[[DOPR]]
                  </li>
                  <li class="featured list-item">
                      <h4 class="media-heading">[[25x-NBOMe]]s</h4>
-* [[25B-NBOMe]]
+*[[25B-NBOMe]]
-* [[25C-NBOMe]]
+*[[25C-NBOMe]]
-* [[25D-NBOMe]]
+*[[25D-NBOMe]]
-* [[25I-NBOMe]]
+*[[25I-NBOMe]]
-* [[25N-NBOMe]]
+*[[25N-NBOMe]]
                  </li>
                  <li class="featured list-item">
                      <h4 class="media-heading">Others</h4>
-* [[2C-B-FLY]]
+*[[2C-B-FLY]]
-* [[Bromo-DragonFLY]]
+*[[Bromo-DragonFLY]]
-* [[ßk-2C-B]]
+*[[ßk-2C-B]]
-* [[TMA-2]]
+*[[TMA-2]]
-* [[TMA-6]]
+*[[TMA-6]]
              </ul>
          </div>
      </div>
-     <div class='flex-column'>
+     <div class="flex-column">
          <div class="panel radius">
              <h3 class="panel-header">[[Entheogens]] [[File:users.svg|x20px|right|link=]]</h3>
              <ul class="featured-table">
                  <li class="featured list-item">
-* [[Acacia confusa]]
+*[[Acacia confusa]]
-* [[Ayahuasca]]
+*[[Ayahuasca]]
-* [[Hawaiian baby woodrose]]
+*[[Hawaiian baby woodrose]]
-* [[Iboga]]
+*[[Iboga]]
-* [[Mimosa hostilis]]
+*[[Mimosa hostilis]]
-* [[Morning glory]]
+*[[Morning glory]]
-* [[Psilocybin mushrooms]]
+*[[Psilocybin mushrooms]]
-* [[Yopo]]
+*[[Yopo]]
                  </li>
              </ul>
@@ Line 172: / Line 172: @@
              <ul class="featured-table">
                  <li class="featured list-item">
-* [[5-MeO-DiBF]]
+*[[5-MeO-DiBF]]
-* [[Efavirenz]]
+*[[Efavirenz]]
                  </li>
              </ul>
@@ Line 181: / Line 181: @@
 ==See also==
 *[[Responsible use]]
 *[[Serotonin]]
@@ Line 190: / Line 191: @@
 ==External links==
 *[https://en.wikipedia.org/wiki/Serotonergic_psychedelic Serotonergic psychedelic (Wikipedia)]
 ==Literature==
-* {{cite journal|last1=Nichols|first1=D. E.|title=Psychedelics|journal=Pharmacological Reviews|volume=68|issue=2|year=2016|pages=264–355|issn=1521-0081|doi=10.1124/pr.115.011478}}
-* {{cite journal|last1=Geyer|first1=M.A.|last2=Nichols|first2=D.E.|last3=Vollenweider|first3=F.X.|title=Serotonin-Related Psychedelic Drugs|year=2009|pages=731–738|doi=10.1016/B978-008045046-9.01160-8}}
+*{{cite journal|last1=Nichols|first1=D. E.|title=Psychedelics|journal=Pharmacological Reviews|volume=68|issue=2|year=2016|pages=264–355|issn=1521-0081|doi=10.1124/pr.115.011478}}
-* Nichols, C. D., & Sanders-Bush, E. (2001). "Serotonin Receptor Signaling and Hallucinogenic Drug Action". Heffter Rev Psychedelic Res, 2, 73-79. https://web-beta.archive.org/web/20170110205041/https://heffter.org/docs/hrireview/02/chap5.pdf
+*{{cite journal|last1=Geyer|first1=M.A.|last2=Nichols|first2=D.E.|last3=Vollenweider|first3=F.X.|title=Serotonin-Related Psychedelic Drugs|year=2009|pages=731–738|doi=10.1016/B978-008045046-9.01160-8}}
-* {{cite journal|last1=Halberstadt|first1=Adam L.|title=Recent advances in the neuropsychopharmacology of serotonergic hallucinogens|journal=Behavioural Brain Research|volume=277|year=2015|pages=99–120|issn=01664328|doi=10.1016/j.bbr.2014.07.016}}
+*Nichols, C. D., & Sanders-Bush, E. (2001). "Serotonin Receptor Signaling and Hallucinogenic Drug Action". Heffter Rev Psychedelic Res, 2, 73-79. https://web-beta.archive.org/web/20170110205041/https://heffter.org/docs/hrireview/02/chap5.pdf
-* {{cite journal|last1=Beique|first1=J.-C.|last2=Imad|first2=M.|last3=Mladenovic|first3=L.|last4=Gingrich|first4=J. A.|last5=Andrade|first5=R.|title=Mechanism of the 5-hydroxytryptamine 2A receptor-mediated facilitation of synaptic activity in prefrontal cortex|journal=Proceedings of the National Academy of Sciences|volume=104|issue=23|year=2007|pages=9870–9875|issn=0027-8424|doi=10.1073/pnas.0700436104}}
+*{{cite journal|last1=Halberstadt|first1=Adam L.|title=Recent advances in the neuropsychopharmacology of serotonergic hallucinogens|journal=Behavioural Brain Research|volume=277|year=2015|pages=99–120|issn=01664328|doi=10.1016/j.bbr.2014.07.016}}
-* {{cite journal|last1=Winter|first1=J.C|last2=Fiorella|first2=D.J|last3=Timineri|first3=D.M|last4=Filipink|first4=R.A|last5=Helsley|first5=S.E|last6=Rabin|first6=R.A|title=Serotonergic Receptor Subtypes and Hallucinogen-Induced Stimulus Control|journal=Pharmacology Biochemistry and Behavior|volume=64|issue=2|year=1999|pages=283–293|issn=00913057|doi=10.1016/S0091-3057(99)00063-5}}
+*{{cite journal|last1=Beique|first1=J.-C.|last2=Imad|first2=M.|last3=Mladenovic|first3=L.|last4=Gingrich|first4=J. A.|last5=Andrade|first5=R.|title=Mechanism of the 5-hydroxytryptamine 2A receptor-mediated facilitation of synaptic activity in prefrontal cortex|journal=Proceedings of the National Academy of Sciences|volume=104|issue=23|year=2007|pages=9870–9875|issn=0027-8424|doi=10.1073/pnas.0700436104}}
-* {{cite journal|last1=Nichols|first1=David E.|last2=Nichols|first2=Charles D.|title=Serotonin Receptors|journal=Chemical Reviews|volume=108|issue=5|year=2008|pages=1614–1641|issn=0009-2665|doi=10.1021/cr078224o}}
+*{{cite journal|last1=Winter|first1=J.C|last2=Fiorella|first2=D.J|last3=Timineri|first3=D.M|last4=Filipink|first4=R.A|last5=Helsley|first5=S.E|last6=Rabin|first6=R.A|title=Serotonergic Receptor Subtypes and Hallucinogen-Induced Stimulus Control|journal=Pharmacology Biochemistry and Behavior|volume=64|issue=2|year=1999|pages=283–293|issn=00913057|doi=10.1016/S0091-3057(99)00063-5}}
-* Canal, C. E., & Murnane, K. S. (2017). The serotonin 5-HT2C receptor and the non-addictive nature of classic hallucinogens. Journal of Psychopharmacology, 31(1), 127-143. https://doi.org/10.1177/0269881116677104
+*{{cite journal|last1=Nichols|first1=David E.|last2=Nichols|first2=Charles D.|title=Serotonin Receptors|journal=Chemical Reviews|volume=108|issue=5|year=2008|pages=1614–1641|issn=0009-2665|doi=10.1021/cr078224o}}
+*Canal, C. E., & Murnane, K. S. (2017). The serotonin 5-HT2C receptor and the non-addictive nature of classic hallucinogens. Journal of Psychopharmacology, 31(1), 127-143. https://doi.org/10.1177/0269881116677104
 ==References==
-<references/>
+<references />
 [[Category:Psychedelic]]